Novo Nordisk Submits FDA Application for 7.2 mg Dose of WEGOVY Injection
Novo Nordisk has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a higher, investigational 7.2 mg dose of its once-weekly semaglutide injection, marketed as WEGOVY, for chronic weight management in adults with obesity. This submission is notable because it is being reviewed under the FDA’s Commissioner’s National Priority Voucher (CNPV) pilot program, an expedited pathway designed to accelerate the review of products addressing major national health priorities, such as the growing public health issue of obesity.
The a...